Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles: 2021-2024

Historic Amortizatization of Intangibles for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $9.9 million.

  • Amylyx Pharmaceuticals' Amortizatization of Intangibles fell 46.07% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 41.15%. This contributed to the annual value of $9.9 million for FY2024, which is 0.85% down from last year.
  • Amylyx Pharmaceuticals' Amortizatization of Intangibles amounted to $9.9 million in FY2024, which was down 0.85% from $9.9 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $9.9 million during FY2023, with a 5-year trough of -$121,000 in FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Amortizatization of Intangibles value was $9.9 million (recorded in 2024), while the average stood at $7.3 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Amortizatization of Intangibles soared by 1,799.17% in 2022 and then decreased by 0.85% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Amortizatization of Intangibles stood at -$121,000 in 2021, then spiked by 1,799.17% to $2.1 million in 2022, then skyrocketed by 383.46% to $9.9 million in 2023, then dropped by 0.85% to $9.9 million in 2024.